Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome.
Shetzline, Susan E, Martinand-Mari, Camille, Reichenbach, Nancy L et al. · Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2002 · DOI
Quick Summary
Researchers found that ME/CFS patients have a smaller, altered form of a protein called RNase L in their immune cells compared to healthy people. This smaller protein (37-kDa) appears to work similarly to the normal-sized protein (80-kDa) in healthy controls, particularly in how it binds to immune signaling molecules. This discovery suggests that ME/CFS may involve a structural change in this immune system protein.
Why It Matters
Identifying structural abnormalities in RNase L—a key component of the antiviral interferon response—provides molecular evidence that ME/CFS involves dysregulation of immune signaling pathways. This work supports the biological basis of ME/CFS and may help explain the immune dysfunction observed in the disease, potentially opening avenues for targeted therapies.
Observed Findings
A 37-kDa form of RNase L is present in PBMC from ME/CFS patients, distinct from the 80-kDa form in healthy controls.
The 37-kDa RNase L forms a catalytically inactive heterodimer complex with RNase L inhibitor (RLI), similar to the 80-kDa form.
Peptide mass fingerprinting identified three peptide masses in the 37-kDa protein matching predicted peptides from the 80-kDa RNase L.
The 37-kDa RNase L shares structural features with 80-kDa RNase L at the N-terminus (2-5A binding domain) and catalytic domains.
The 37-kDa variant is not generated by alternative splicing based on RT-PCR and Southern blot analysis.
Inferred Conclusions
The 37-kDa RNase L in ME/CFS patients is structurally similar to normal RNase L, particularly in functional domains, suggesting it is a modified form rather than a completely different protein.
The 37-kDa RNase L retains the ability to bind its natural inhibitor (RLI), indicating preserved protein-protein interaction capacity.
The mechanism generating the 37-kDa variant does not involve alternative splicing, suggesting post-translational modification or proteolytic cleavage.
Remaining Questions
What specific post-translational modification or cleavage generates the 37-kDa RNase L variant from the 80-kDa precursor?
What This Study Does Not Prove
This study does not prove that the 37-kDa RNase L variant causes ME/CFS; it only demonstrates an association. The study does not show whether this protein variant directly contributes to symptoms, whether it is present in all ME/CFS patients, or how the variant arises mechanistically. Cross-sectional biochemical characterization alone cannot establish causality or determine if the variant is primary or secondary to disease processes.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Does the presence of the 37-kDa RNase L variant correlate with disease severity, symptom type, or patient subgroups?
Is the 37-kDa variant present in all ME/CFS patients, or only a subset, and does its abundance change with disease progression or treatment?
Does the truncated form have altered enzymatic activity or differential responsiveness to 2-5A signaling that could explain immune dysfunction in ME/CFS?